PollakPTSketrisISMacKenzieSLHewlettTJ, Delirium probably induced by clarithromycin in a patient receiving fluoxetine. Ann Pharmacother1995; 29:486–8.
2.
StevensJCWrightonSA, Interaction of the enantiomers of fluoxetine and norfluoxetine with human liver cytochrome P450. J Pharmacol Exp Ther1993; 226:964–71.
3.
OhmoriSIshiiIKuriyaSTanguchiTRikihistaTHiroseS, Effects of clarithromycin and its metabolites on the mixed function oxidase system in hepatic microsomes of rats. Drug Metab Dispos1993; 21:358–63.
4.
GillumJGIsraelDSPolkRE, Pharmacokinetic drug interactions with antimicrobial agents. Clin Pharmacokinet1993; 25:450–82.
5.
BergstromRFLembergerLFaridNAWolenRL, Clinical pharmacology and pharmacokinetics of fluoxetine: A review. Br J Psychiatry1988; 153(suppl 3):47–50.
6.
BenetLZØieSSchwartzJB, Appendix II: Design and optimization of dosage regimens; pharmacokinetic data. In: HardmanJGLimbirdLEMolinoffPBRuddonRWGilmanAG, eds. Goodman and Gilman's the pharmacological basis of therapeutics. 9th ed.New York: McGraw-Hill, 1996:1707–92.
7.
RingBJBinkleySNRoskosLWrightonSA, Effect of fluoxetine, norfluoxetine, sertraline, and desmethyl sertraline on human CYP3A4 catalyzed 1′-hydroxy midazolam formation in vitro. J Pharmacol Exp Ther1995; 275:1131–5.